Opting Out to Opt In: Harvard Medical Withdraws From U.S. News and World Report Rankings

Some things are changing in the higher education world. From #1 in research to #9 in primary care in the most recent U.S. News and World Report, Harvard’s medical school is opting out of future participation in the list. Is Harvard alone? No.

As more top schools, such as Georgetown Law, UC Berkeley Law, and Yale Law, among others, opt out of the ranking system, what is making them leave? For Harvard medical, leaving means opting into student output and opting out of rankings. In other words, Harvard medical is putting the student first.

Harvard wants students to pick the school the works best for their individual, unique experiences. A ranking can’t demonstrate how each student will fit into the environment. For more insight on this choice and the future of the workforce, Host of Future of Education, Michael Horn, provides his thoughts.

 

Michael’s Thoughts:

“The biggest news right now in the world of Higher Education is Harvard Medical School’s decision, I think to say they’re no longer going to participate in the US News in World Report rankings. They’re joining a course of law schools that have recently opted out of those rankings. And in my mind, this just adds to the backlash, if you will, against the US News and World Report rankings.

And while I thought that the reasons offered for some of the law schools leaving the ranking, were a bit empty and, I’m sure Harvard Medical School, some of this has to do with other currents as well. I will say, I thought the quote from their dean was right on the money, which was basically that a crude rankings list misses all the different contexts and motivations, and reasons that a student might choose a particular school, and that relying on rankings is frankly going to mislead them.

Because it’s not gonna really correspond to their personal context and circumstances. And so ultimately you ought to be picking a school based on what works for you. And on the flip side, for employers and the like, trying to make sure that you’re picking graduates based on what they can do, not where they went, I think is the ultimate best scenario.

So getting out of these ranking lists that are crude and focused obsessively on the inputs rather than the student outcomes, I think is a very good move.”

 

Article written by Marissa Martin

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More